Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Risk of a leukemia diagnosis was found to be highest between 3 to 6 years following manifestation of symptoms associated with dengue viral infection.
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
The JAK-STAT pathway as well as epigenetics may play a role in the development of breast implant–associated anaplastic large-cell lymphoma.
Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Patients with CLL who have complex karyotype appear to have better clinical outcomes with venetoclax and obinutuzumab compared with chlorambucil and obinutuzumab.
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Researchers hypothesized that imbalances of toxic and essential metals in patients with acute myeloid leukemia may be associated with poorer survival.